Dr Mark Trozzi（マーク・トロッツィ博士）がCOVID-19 mRNAワクチンによる障害報告に関する査読済み論文の約1,000件を掲載したサイトを作っています。
1000 peer reviewed articles on “Vaccine” injuries
その中で5番目に多くの件数が報告されている「血管炎（Vasculitis）」の論文リストを転載させていただきます。
「顕微鏡的多発血管炎」という用語が含まれます。 血管壁に変化を引き起こす血管の炎症。 血管が弱ると、血管が伸びて膨らむことがあります（動脈瘤と呼ばれます）。 また、破裂して出血を引き起こす可能性もあります。 これは生命を脅かす可能性があります。
血管炎症候群とは、血管に炎症が起こることにより多彩な臓器障害を呈する疾患群であり、炎症が起こっている血管のサイズにより、小型血管炎（顕微鏡的多発血管炎、好酸球性多発血管炎性肉芽腫症、多発血管炎性肉芽腫症など）、中型血管炎（結節性多発動脈炎など）、大型血管炎（高安動脈炎、巨細胞性動脈炎）に大別されます。共通の症状である発熱や倦怠感、体重減少に加えて、炎症が起こっている血管の種類により様々な症状（例えば、手足の神経を栄養する血管で炎症が起こっている場合、しびれや感覚の低下、筋力の低下など（＝末梢神経障害）が起こります）を呈します。
総論文数: 43
ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine:
https://www.sciencedirect.com/science/article/pii/S0272638621007423
propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination:
https://pubmed.ncbi.nlm.nih.gov/34451967/
IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34509658/
A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34196469/
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?:
https://pubmed.ncbi.nlm.nih.gov/34416184/
Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant):
https://pubmed.ncbi.nlm.nih.gov/34546608/
Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine:
https://pubmed.ncbi.nlm.nih.gov/34853744/
Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients:
https://pubmed.ncbi.nlm.nih.gov/34755433/
Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality:
https://pubmed.ncbi.nlm.nih.gov/34726187/
Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination:
https://pubmed.ncbi.nlm.nih.gov/34859017/
Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report:
https://pubmed.ncbi.nlm.nih.gov/34783899/
COVID-19 vaccine-induced urticarial vasculitis:
https://pubmed.ncbi.nlm.nih.gov/34369046/
ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine:
https://pubmed.ncbi.nlm.nih.gov/34280507/
New-onset leukocytoclastic vasculitis after COVID-19 vaccine:
https://pubmed.ncbi.nlm.nih.gov/34241833/
Cutaneous small vessel vasculitis after COVID-19 vaccine:
https://pubmed.ncbi.nlm.nih.gov/34529877/
Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine:
https://pubmed.ncbi.nlm.nih.gov/33928638/
Leukocytoclastic vasculitis after exposure to COVID-19 vaccine:
https://pubmed.ncbi.nlm.nih.gov/34836739/
Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?:
https://pubmed.ncbi.nlm.nih.gov/34495381/
Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine:
https://pubmed.ncbi.nlm.nih.gov/34327795
Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine:
https://pubmed.ncbi.nlm.nih.gov/34660867/
Reactivation of IgA vasculitis after vaccination with COVID-19
https://pubmed.ncbi.nlm.nih.gov/34848431/
Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34310759/
Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster:
https://pubmed.ncbi.nlm.nih.gov/34720009/
Cutaneous vasculitis following COVID-19 vaccination:
https://pubmed.ncbi.nlm.nih.gov/34611627/
Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis:
https://pubmed.ncbi.nlm.nih.gov/34705320/
IgA vasculitis following COVID-19 vaccination in an adult:
https://pubmed.ncbi.nlm.nih.gov/34779011/
Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19:
https://pubmed.ncbi.nlm.nih.gov/34451967/
Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis:
https://pubmed.ncbi.nlm.nih.gov/33928459/
Reactivation of IgA vasculitis after COVID-19 vaccination:
https://pubmed.ncbi.nlm.nih.gov/34250509/
First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report:
https://pubmed.ncbi.nlm.nih.gov/34530771/
Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: https://pubmed.ncbi.nlm.nih.gov/34245294/
Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34599716/
Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils:
https://pubmed.ncbi.nlm.nih.gov/34115904/
Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine:
https://pubmed.ncbi.nlm.nih.gov/34237323/
A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19
https://pubmed.ncbi.nlm.nih.gov/34849386/
Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-19
https://pubmed.ncbi.nlm.nih.gov/34310763/
Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine:
https://pubmed.ncbi.nlm.nih.gov/34557622/
Leukocytoclastic vasculitis after coronavirus disease vaccination 2019:
https://pubmed.ncbi.nlm.nih.gov/34713472/803
Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2:
https://pubmed.ncbi.nlm.nih.gov/34819272/
Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34337124/
Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019:
https://pubmed.ncbi.nlm.nih.gov/34535924/
Relapse of microscopic polyangiitis after COVID-19 vaccination: case report:
https://pubmed.ncbi.nlm.nih.gov/34251683/
